PLUS THERAPEUTICS, INC.

PSTV

CIK 0001095981 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$1M
↓-3.2% -$45Kvs FY2024 (Q4)
Gross Profit
$1M
↓-3.2% -$45Kvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
39/100
  • Profitability
    100ROIC 488.0% (10% = solid, 20%+ = moat)
  • Liquidity
    37Current Ratio 1.23 (above 1.5 = solid)
  • Leverage
    71D/E 0.59 (under 0.5 = conservative)
  • Efficiency
    20Asset Turnover 0.45x (1.0+ = capital-efficient)
  • Growth
    6Revenue YoY -3.2% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -320.8% · trend -6.2pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$67K
investment in PP&E
Stock buybacks (TTM)
share count reduction
Stock-based comp (TTM)
$2M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$16M
everything owned
Total liabilities
$12M
everything owed
Stockholders' equity
$4M
shareholder claim
Net debt
$-470K
Net cash position ($470K)

Recent performance · 63 quarters

Revenue↓-3.2% -$45K
$1M
Net Income↓-53.9% -$2M
$-4M
Free Cash Flow↓-172.7% -$19K
$-30K
Operating Margin↓-59.9pts
-320.8%

Drill down